OBJECTIVE: Prandial glucose regulation has the potential for achieving good metabolic control with a low risk of hypoglycaemia and increased¯exibility with regard to eating patterns. Comparative studies have suggested that the prandial glucose regulator repaglinide is at least equivalent to sulphonylureas in terms of ef®cacy, but incurs a lower risk of major hypoglycaemia. However, these trials employed ®xed dosing and mealtime regimens, so repaglinide was not used as intended. This prospective investigation in a daily clinical setting aimed to assess the ef®cacy and tolerability pro®le of¯exible prandial glucose regulation with repaglinide in Type 2 diabetes. DESIGN: 5985 patients with Type 2 diabetes in Germany were surveyed prospectively. These patients were assessed before and after a mean of 46 days treatment with repaglinide. At baseline, available data showed that 64% of patients had previously received therapy with conventional oral antidiabetic drugs, 22% were on diet alone, and 13% were naõ Ève to any treatment. RESULTS: Overall, mean HbA 1c decreased from 8.6 to 7.4%, fasting blood glucose from 183.9 to 134.2 mgadl (10.2 to 7.4 mmolal), blood glucose prior to main meals from 198.5 to 141.4 mgadl (11 to 7.8 mmolal), and blood glucose 2 hours after main meals from 219.3 mgadl to 153.2 mgadl (12.2 to 8.5 mmolal).
Introduction
A fundamental aspect of the pathophysiology of Type 2 diabetes is progressive attenuation of the prandial insulin response Ð particularly its early phase. 1 ± 6 Failure to reduce postprandial plasma glucose peaks to physiological levels within the time periods afforded by the eating patterns of the patient results in continuous hyperglycaemia. Furthermore, there is evidence that the high postprandial peaks in plasma glucose concentration may be directly damaging to vascular structure 7 ± 11 and hence incur cardiovascular risk. 10,12 ± 15 A logical approach to the treatment of Type 2 diabetes therefore, would be to use either exogenous insulin or insulin secretagogue therapy to recreate the physiological prandial insulin response. However, conventional insulin secretagogues, the sulphonylureas, are traditionally dosed so as to maintain a`therapeutic' plasma concentration across dosing intervals, 16 and they have a pharmacological action that is not nutrient-dependent. 17 ± 19 Consequently, there is an inherent risk of hypoglycaemia. To counteract this risk, patients are required to eat meals at regular intervals supplemented by carbohydrate snacks. Thus, not only may the time ± action pro®le of sulphonylurea therapy be inappropriate given the dynamic insulin requirements of the patient, the treatment also creates lifestyle restrictions. The perceived convenience of once-or twice-daily dosing is offset by the rigid compensatory eating regimen necessary to avoid hypoglycaemia. Repaglinide is a carbamoylmethyl benzoic acid (CMBA) derivative that has been developed in an attempt to address these shortcomings of the sulphonylureas. Like sulphonylureas, it increases the secretion of endogenous insulin from pancreatic beta-cells by blocking ATP-gated potassium channels. 20 However, in contrast to sulphonylureas its action is, at least in part, glucose-mediated. 18 Its kinetic pro®le is characterized by rapid absorption and relatively fast elimination producing a fast onset and relatively short duration of action. 20 ± 22 Therefore, repaglinide can be taken prior to main meals, whenever they are eaten, to enhance the immediate prandial insulin response. The antidiabetic potential of repaglinide has been demonstrated in a series of prospective, controlled, randomised trials. Placebo-controlled studies have consistently shown repaglinide to improve all measured parameters of glycaemic control. 23 ± 25 Two studies have examined the use of repaglinide in varied dosing regimens and have con®rmed the feasibility of a¯exible prandial glucose regulation strategy for achieving overall glycaemic control. 26, 27 Repaglinide has also been studied in prospective, randomised, double-blind trials in comparison to sulphonylureas. These have shown repaglinide to provide an antidiabetic ef®cacy at least equivalent to comparator sulphonylureas, 28 ± 31 but with a lower risk of major hypoglycaemia. 32 However, these comparative trials may have been misleading. In order to maintain blinding, it was necessary to give doses (or placebo) in ®xed regimens, with mealtimes and consumption of snacks controlled in line with the requirements of sulphonylurea therapy. Thus, in these studies, repaglinide was not used as intended Ð as a¯exible prandial glucose regulator, taken with the patient's choice of mealtimes. It is therefore possible that the antidiabetic ef®cacy and risk of hypoglycaemia of repaglinide in relation to ®xed-dose regimens of sulphonylureas might have been either over-or under-estimated. Furthermore, the issue of whether or not patients found ®xed eating regimens burdensome was not investigated in these comparative trials.
The aim of the present investigation was to assess the clinical ef®cacy and tolerability pro®le of repaglinide when used as intended in everyday clinical practice. An additional goal was to assess patient attitudes towards the¯exible dosing and mealtime regimen afforded by repaglinide, to establish whether this greater¯exibility is perceived as a special bene®t.
Patients and methods
This uncontrolled, prospective investigation in a daily clinical setting in primary care assessed a large cohort of patients with Type 2 diabetes in Germany. These patients were receiving treatment with repaglinide, either as monotherapy or in combination with other oral hypoglycaemic agents (OHAs). A total of 1256 participating physicians in Germany were asked to collect data concerning patients who were about to be put on repaglinide at the physician's discretion. Data were provided representing a cohort of 5985 patients. Each analysis was based on only those patients for whom relevant data had been provided. Patients assessed their blood glucose levels using self-monitoring of blood glucose. Before commencing repaglinide, demographic information about the patient was recorded, together with details of their previous therapy. The patients' body weight, HbA 1c , fasting blood glucose concentration (FBG), immediate preprandial blood glucose concentration (PrePBG) and 2-hour postprandial blood glucose concentration (PostPBG) were also recorded at baseline and after a follow-up period (mean 46 AE 27 days) of repaglinide therapy if assessed during routine treatment. In addition, patients were asked to complete a questionnaire at baseline and on completion of follow-up containing diabetesrelated questions about their attitudes to mealtime and treatment regimens. The follow-up questionnaire repeated some of the original questions, but incorporated further questions relating to the patient's experiences with repaglinide.
Analyses were made of changes in glycaemic control and tolerability (including body weight change) and qualitative assessments were made regarding patient-acceptance of the treatment regimen and perceptions of lifestyle restriction. The large number of subjects allowed a number of subgroup analyses (by treatment status) to ascertain potential differences in the clinical pro®le of repaglinide. Important subgroups identi®ed included patients who had not received prior treatment with any alternative OHA (therapy-naõ Ève patients), patients who changed from an alternative OHA to repaglinide (switched patients) and patients who took repaglinide in addition to other OHAs (combination therapy patients).
Repaglinide was given prandially and dosed empirically by the participating physicians. The most popular starting doses were 0.5 mgameal (38% of the patients), 1 mgameal (42.4%), and 2 mgameal (10.3%). In some patients, dose adjustments were made: last recorded doses per meal indicated that 23.9% were receiving 0.5 mgameal, 40.2% were receiving 1 mgameal and 18.5% were receiving 2 mgameal. Doses for the remainder of the patients were either unrecorded, or were higher than 2 mgameal up to a maximum of 4 mgameal (2.2%). At endpoint, the mean dose per meal was 1.2 mg, with a mean of 2.7 meals per day. Thus, the mean total daily dose of repaglinide was 3.0 AE 2.0 mg.
Results

Baseline demographic and treatment status pro®les
The investigation cohort typi®ed a European population with Type 2 diabetes. The sex ratio was 51.4%
Prandial glucose regulation in Type 2 diabetes R Landgraf et al male: 46.3% female with gender unrecorded for 2.3%. Mean age was 61.2AE 10.8 y, mean height 169.8AE 8.5 cm, and mean weight 82.1AE 14.3 kg. The mean time since onset of diabetes differed between the therapy-naõ Ève (2.6 AE 4.5 y) and pre-treated subjects (6.8AE 5.7 y).
At baseline, 3802 patients (64% of records) had been taking an alternative OHA (most commonly, a sulphonylurea, Figure 1) , 1337 (22.3%) had been treated with dietary modi®cation only, and 754 patients (12.6%) had received no form of therapy at all. Only 77 patients had previously received insulin ( AE an OHA). The majority of patients previously treated with OHAs discontinued their prior therapy when switching to repaglinide, so the major subgroups at endpoint comprised 2091 therapy-naõ Ève patients, 2180 switched patients and 1530 combination therapy patients. Predictably, most patients (91.5%) previously treated with sulphonylureas were switched to repaglinide, whereas 67.5% of patients previously treated with metformin had repaglinide added to their treatment regimen (Figure 1) . Nevertheless, because all therapy-naõ Ève patients were given repaglinide as monotherapy, the vast majority of patients at endpoint were receiving repaglinide as monotherapy (74% of those for whom data were available). Table 1 shows the values for parameters of glycaemic control measured before and after treatment with repaglinide. Signi®cant improvements (P 0.0001) were evident in every parameter measured in every patient category. In addition to improved metabolic control in therapy-naõ Ève patients, signi®cant improvement was evident in patients switched from sulphonylureas, metformin and acarbose, as well as in patients in which repaglinide was added as combination therapy to metformin, acarbose or sulphonylureas. The changes in indices of control in the overall cohort (in mgadl for blood glucose concentrations) are shown graphically in Figure 2 .
Metabolic control
Tolerability and weight change
Adverse drug reactions were rare, and totalled 95 overall. Half of these adverse drug reactions were reports of hypoglycaemia (n 49), of which 38 cases were reported as mild, four as moderate and ®ve as severe. Eight cases of hypoglycaemia (16% of the total) occurred among the 26% of patients taking combination therapy. Of the ®ve severe hypoglycae- Figure 3 . There were small non-signi®cant reductions in body weight in all patient categories. Overall, body weight decreased by 1.2 AE 2.65 kg, and a correlation with glycaemic control was found. Another predictor of weight loss was the patient's weight at baseline, ie the heaviest patients lost the most weight over the investigation period ( Figure 3 ).
Eating behaviour
Overall, the majority of patients (62.3%) reported taking three main meals per day as their most common eating pattern, with 15% taking two main meals per day, and only 5.6% and 2.3% taking one or four meals per day respectively. These ®gures varied little between the therapy-status subgroups and changed little between baseline and follow-up. Nevertheless, 77.2% of patients overall reported a sense of relief that they could miss or delay meals under repaglinide treatment and 40.4% reported that they had taken the opportunity to change their eating habits. Indeed, repaglinide was associated with an increase in the percentage of patients who reported varying their mealtimes. In the overall cohort 57.4% reported taking their meals at the same time each day at baseline, with this ®gure declining to 46.9% at follow-up. The likelihood of patients changing their habit of regular mealtimes was greater in patients switched from other OHAs (from 61.1% to 47.8%) than in therapy-naõ Ève patients (from 51.4% to 44.8%).
Interestingly, fewer patients reported taking their meals at regular times each day when put on combination therapy (60.3% at baseline; 49.2% at followup). Regular mealtimes may be a matter of patient preference rather than obligation, therefore the 2843 patients who reported following regular mealtimes were asked the question,`do you feel restricted by regular mealtimes?' The results, depicted in Figure 4 , indicate that many patients were following regular mealtimes only as a matter of obligation to their treatment. In particular, 39% of sulphonylurea-treated patients regarded regular mealtimes as restrictive before switching to repaglinide (after which only 7.2% still felt this restriction).
There was a considerable discrepancy in the number of snacks eaten per day (Table 2) . Predictably, there was evidence that patients treated with OHAs (particularly those receiving sulphonylureas) consumed more snacks at baseline than therapy-naõ Ève patients. There were also indications that during treatment with repaglinide patients reduced the (Table 2 ). This was borne out by patients' responses to the question,`do you sometimes eat when not hungry for fear of hypoglycaemia?' ( Figure 5 ). There was a notable decline in the number of patients responding`yes' to this question after treatment with repaglinide, with the impact being particularly great in patients switched from sulphonylureas (from 41% to 9.8%).
Discussion
The present investigation clearly demonstrates that the use of repaglinide as a¯exible, prandial glucose regulator is associated with a positive impact upon both glycaemic control and patient lifestyle. Therapynaõ Ève patients started on repaglinide can expect to gain signi®cant improvements in glycaemic control, while patients switched from alternative OHAs, particularly sulphonylureas, can bene®t not only from improved glycaemic control but also from a greater freedom with regard to eating behaviour. The majority of patients in the present investigation chose to have three main meals per day. This meal pattern is customary in European cultures and forms the basis for the rigid meal pattern required during sulphonylurea therapy. It was hence used in previous comparative trials of repaglinide. 28 ± 31 However, in contrast to earlier comparative studies, mealtimes were varied on a daily basis by more than 50% of patients in the present investigation. Nevertheless, signi®cant improvements in all parameters of glycaemic control were apparent in all patient categories. In some poorly-controlled patients, repaglinide was added to existing OHA therapy Ð most commonly to metformin. Again, glycaemic control improved signi®cantly in such patients without a disproportionate increase in the frequency of hypoglycaemic events. This ®nding con®rms the clinical usefulness of the repaglinide ± metformin combination previously reported in a controlled study. 33 Figure 4 Percentage of patients following regular mealtimes who felt restricted by this practice, at baseline and after a mean of 46 days treatment with repaglinide. n number of patients at baselineanumber of patients at follow-up for whom data were available. (SU, sulphonylurea). Figure 5 Percentage of patients responding,`yes' to the question,`do you sometimes eat when not hungry for fear of hypoglycaemia?' at baseline and after a mean of 46 days treatment with repaglinide.
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The tolerability pro®le of repaglinide revealed by this investigation was also impressive, with just 0.8% of patients (for whom data were available) reporting hypoglycaemic events. Although the mean follow-up period was 46 days, this incidence appears to be lower than has been reported in some comparative trials with sulphonylureas (as discussed by Nattrass and Lauritzen 34 in this publication) and may imply that the empirical, prandial use of repaglinide incurs a lower risk of hypoglycaemia than has been previously suggested by ®xed-regimen comparative studies.
Also welcome was the ®nding that improved glycaemic control was not associated with weight gain. Indeed, there was a trend towards weight loss in all categories, particularly among the heavier patients. This might relate to changes in eating behaviour, with a reduction in snacking being noted in patients switched from previous OHAs to repaglinide. Although patients' feelings about weight loss were not investigated, it is likely that the ability to lose weight would have been perceived as a welcome effect of the therapy change. Clinical experience suggests that patients are often confused and disheartened by the apparently contradictory advice to lose weight yet take regular snacks during sulphonylurea therapy. The results of the present investigation are consistent with two previous studies in which¯exible prandial glucose regulation with repaglinide was associated with improved control without weight gain. 26, 27 Two key changes in eating habit were apparent among patients in the present survey. As well as taking fewer snacks, some patients took the opportunity to vary the times of their main meals. Of note was the marked decrease in patients snacking for fear of hypoglycaemia. Patients switched to repaglinide from sulphonylureas, or even those put on combination therapy, were less likely to report snacking for fear of hypoglycaemia after therapy change than were therapy-naõ Ève patients at baseline. The sense of liberation was, predictably, most marked in patients switched from alternative OHAs. Indeed, this investigation has clearly demonstrated that the need for regular meals supplemented by snacks is a source of restriction and anxiety for many patients and that switching to repaglinide provides an opportunity for these patients to change to favoured eating patterns that can facilitate weight loss. The greater freedom afforded by prandial glucose regulation with repaglinide can therefore be seen as a major advantage over sulphonylureas, one that has not been highlighted by comparative trials.
It is encouraging to speculate that the instigation of prandial glucose regulation was taken as a cue by physicians to improve their patients' understanding of their disease management. A recent survey of OHAtreated patients with Type 2 diabetes in Europe and the USA has revealed that patients have many misconceptions about their treatment and are anxious to obtain more information. 35 Many patients did not realise that regular meals and snacks were a treatment requirement with their sulphonylurea therapy to avoid hypoglycaemia. Instead, there was a widespread misconception that regular eating and snacking was needed to improve metabolic control. This international survey also suggested that patients ®nd changing their eating behaviour to be among the most dif®cult lifestyle changes to make.
In conclusion, prandial glucose regulation with repaglinide was shown in a large cohort of patients to be an effective and well-tolerated therapy. It was associated with signi®cant improvements in glycaemic control, without weight gain and with a very low incidence of hypoglycaemia. Patients' attitudes to this therapy were positive, with 94.1% continuing their treatment beyond endpoint of this study. Prandial glucose regulation with repaglinide was regarded as convenient, and patients switched from alternative OHAs often found the experience liberating.
